Next Article in Journal
Four New Insecticidal Xanthene Derivatives from the Mangrove-Derived Fungus Penicillium sp. JY246
Previous Article in Journal
Piltunines A–F from the Marine-Derived Fungus Penicillium piltunense KMM 4668
Previous Article in Special Issue
Biomaterials Based on Marine Resources for 3D Bioprinting Applications
Open AccessArticle

Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay

1
Department of Cancer Biology, Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM) 28029 Madrid, Spain and University Hospital La Paz Institute for Health Research (IdiPAZ), 28046 Madrid, Spain
2
Biomedical Research Networking Centres-Oncology (CIBERONC), 28029 Madrid, Spain
3
General Surgery and Pathology Services, University Hospital La Paz, 28046 Madrid, Spain
*
Author to whom correspondence should be addressed.
Mar. Drugs 2019, 17(11), 648; https://doi.org/10.3390/md17110648
Received: 23 October 2019 / Revised: 14 November 2019 / Accepted: 15 November 2019 / Published: 19 November 2019
(This article belongs to the Special Issue 3D Cell Culture Based on Marine Resources)
Plocabulin is a novel microtubule-disrupting antitumor agent of marine origin that is currently undergoing phase II clinical trials. Plocabulin has potent antiproliferative and antiangiogenic actions in carcinoma cell lines and has antitumor activity in xenografted mice. Here, we used three-dimensional (3D) tumor organoids derived from three colorectal cancer (CRC) patients to study the effect of plocabulin in a personalized assay system that ensures dose dependence and high reproducibility. The cytotoxicity of plocabulin was an order of magnitude higher than that of the active irinotecan derivative SN38 (7-ethyl-10-hydroxy-camptothecin) in tumor organoids at different passages. Moreover, plocabulin maintained its strong cytotoxic activity in wash-out experiments, in which a short pulse treatment of tumor organoids was as efficient as continuous treatment. Our data show that plocabulin has a very potent cytotoxic action in CRC patient-derived tumor organoids, supporting ongoing clinical trials with plocabulin and the use of organoid assays to provide personalized validation of antitumor drugs. View Full-Text
Keywords: plocabulin; drug assay; patient-derived organoids; 3D culture; colorectal cancer plocabulin; drug assay; patient-derived organoids; 3D culture; colorectal cancer
Show Figures

Graphical abstract

MDPI and ACS Style

Costales-Carrera, A.; Fernández-Barral, A.; Bustamante-Madrid, P.; Guerra, L.; Cantero, R.; Barbáchano, A.; Muñoz, A. Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay. Mar. Drugs 2019, 17, 648.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop